2015
Veronte was established
2017
Initiate the industrialization of oncolytic virus M1 first VRT106 product
2018
Undertake the national 13th Five-Year major new drug creation project (the first genetic engineering product project)
2022
VRT106 for indications "liver cancer" and "malignant glioma" were approved by the US FDA orphan drug qualification
2022
Oncolytic virus M1 core patent won the silver prize of the 23rd China Patent Award
2023
VRT106 received National Drug Administration (NMPA) clinical trial implied approval
2023
VRT106 Receives Implied Approval for Clinical Trials by Japan's Drug and Medical Device Agency (PMDA)
2024
VRT106 intravenous injection obtained implied approval for clinical trials from the National Medical Products Administration
COMPANY HISTORY
development process